Sökning: onr:"swepub:oai:DiVA.org:uu-506588" > Cross-reactive EBNA...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05322naa a2200505 4500 | |
001 | oai:DiVA.org:uu-506588 | |
003 | SwePub | |
008 | 230628s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:152861661 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5065882 URI |
024 | 7 | a https://doi.org/10.1126/sciadv.adg30322 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1528616612 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Thomas, Olivia G.u Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
245 | 1 0 | a Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis |
264 | 1 | b American Association for the Advancement of Science (AAAS),c 2023 |
338 | a electronic2 rdacarrier | |
520 | a Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, for which and Epstein-Barr virus (EBV) infection is a likely prerequisite. Due to the homology between Epstein-Barr nuclear antigen 1 (EBNA1) and alpha-crystallin B (CRYAB), we examined antibody reactivity to EBNA1 and CRYAB peptide libraries in 713 persons with MS (pwMS) and 722 matched controls (Con). Antibody response to CRYAB amino acids 7 to 16 was associated with MS (OR = 2.0), and combination of high EBNA1 responses with CRYAB positivity markedly in-creased disease risk (OR = 9.0). Blocking experiments revealed antibody cross-reactivity between the homolo-gous EBNA1 and CRYAB epitopes. Evidence for T cell cross-reactivity was obtained in mice between EBNA1 and CRYAB, and increased CRYAB and EBNA1 CD4+ T cell responses were detected in natalizumab-treated pwMS. This study provides evidence for antibody cross-reactivity between EBNA1 and CRYAB and points to a similar cross-reactivity in T cells, further demonstrating the role of EBV adaptive immune responses in MS development. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
700 | 1 | a Bronge, Mattiasu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Tengvall, Katarina,d 1980-u Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi,Science for Life Laboratory, SciLifeLab,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut0 (Swepub:uu)katst103 |
700 | 1 | a Akpinar, Birceu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Nilsson, Ola B.u Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Holmgren, Eriku Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Hessa, Tarau Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Gafvelin, Gurou Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Khademi, Mohsenu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Alfredsson, Larsu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.;Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden.4 aut |
700 | 1 | a Martin, Rolandu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.;Univ Zurich, Inst Expt Immunol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.4 aut |
700 | 1 | a Guerreiro-Cacais, Andre Ortliebu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Grönlund, Hansu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Olsson, Tomasu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut |
700 | 1 | a Kockum, Ingridu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut |
710 | 2 | a Karolinska Institutetb Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 org |
773 | 0 | t Science Advancesd : American Association for the Advancement of Science (AAAS)g 9:20q 9:20x 2375-2548 |
856 | 4 | u https://doi.org/10.1126/sciadv.adg3032y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1776664/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-506588 |
856 | 4 8 | u https://doi.org/10.1126/sciadv.adg3032 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:152861661 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy